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Aims: (a) To investigate the HPSE expression in chronic liver
injury and (b) to study its effects on the fibrosis process.
Materials and methods: 1. Experimental design: CCl4 model
for fibrosiswas utilized in 20BALB/cJmice.2. In vitro studies:HPSE
expression was assayed on macrophages (U937 cell line) by real
time RT-PCR andwestern blot analyses. Furthermore,we evaluated
the HPSE activation of HSCs (LX-2 cell line). Finally, the migration
of macrophages (RAW 264.7 cell line) was assayed by treatment
with HPSE.
Results: HPSE expression in liver tissue of CCl4-treated mice
increased after 1 and 2 weeks of treatment but not after 8 and 12
weeks. Immunostaining analyses revealed thatHPSEwas restricted
in the centrilobular areas with both necro-inflammatory damage
and fibrosis, and co-localized with macrophage markers F4/80
and CD68. TNF- treatment of U937 macrophages significantly
increased HPSE mRNA and protein expression, as well as HPSE
secretion. Using the conditioned medium of TNF--pre-treated
U937, we found that macrophage-secreted HPSE regulated the
expression of both -SMA and fibronectin in LX-2 cells. Finally,
macrophages with latent HPSE significantly increased the cell
migration rate.
Conclusions:Overall, HPSE is involved in early stages of fibrosis
process. Inflammatory macrophages could be an important source
of HPSE. In this context, HPSE may play a role in the macrophage-
mediated activation of HSCs and in migration of macrophages
themselves.
http://dx.doi.org/10.1016/j.dld.2017.01.042
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Introduction: In liver cirrhosis, kidney local renin–angiotensin
system (RAS) deserves scrutiny and includes: conversion of
angiotensin I into angiotensin II (Ang-II) by ACE and chymase;
binding of renin and prorenin to their tissue receptor (RPRr),
and hence local generation of angiotensin I and Ang-II; conver-
sion of Ang-II by ACE2 into angiotensin1-7; degradation of the
latter to angiotensin1-4 by neprilysin. Changes in expression of
these enzymesand receptors affect renal levels of sodium-retentive
(Ang-II) and natriuretic (angiotensin1-7) peptides.
Aims: To assess, in ascitic rats’ kidney, expression and
immunolocation of major components of RAS and their hormonal
consequences.
Methods: Healthy rats (group G1) and rats with ascitic cirrho-
sis due to CCl4 (G2) were studied. Kidney content of ACE, chymase,
RPRr, ACE2, neprilysin, Ang-II, angiotensin1-7 and plasma levels of
Ang-II, direct renin (DR), plasma renin activity (PRA) were mea-
sured. DR is quantified through monoclonal antibodies that bind
both active renin and prorenin, and therefore plasma concentra-
tions of prorenin can be derived from the ratio DR/PRA.
Results: DR/PRA ratios were 3.3±0.8 and 7.9±1.6 in healthy
and ascitic rats, respectively (P<0.03), showing more prorenin in
ascitic rats. InG2,Ang-IIwashigher thannormal inplasma (P<0.01)
but especially in renal tissue (1150±199 vs. 78±22pg/mg kid-
ney protein, P<0.001). Kidney content of ACE, chymase, ACE2 and
neprilysin was significantly higher, but RPRrs significantly lower,
in ascitic than in healthy rats. The ratio Ang-II/Angiotensin1-7 in
kidneys rose from 1.3±0.2 in G1 to 5.3±0.4 in G2 (P<0.03).
Conclusions: In ascitic cirrhosis: (a) the contribution of ACE
and chymase to renal Ang-II synthesis seems stronger than that
of RPRrs, despite increased plasma prorenin; (b) the kidney shows
an imbalance in favour of the production of anti-natriuretic Ang-II
because overexpressed neprilysin finally degrades ACE2-generated
angiotensin1-7.
http://dx.doi.org/10.1016/j.dld.2017.01.043
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Introduction and aim: Obeticholic acid (OCA) is a potent and
selective farnesoid X receptor (FXR) agonist under investigation
for the treatment of primary biliary cholangitis (PBC). This anal-
ysis evaluated the long-term efficacy and safety of OCA in Italian
patients with PBC.
Material and methods: POISE was a Phase 3, 12-month,
double-blind, placebo-controlled study followed by an ongoing
open-label extension (OLE). Patients with an alkaline phosphatase
(ALP) >1.67× ULN and/or bilirubin >ULN to <2× ULN, on a stable
ursodeoxycholic acid (UDCA)doseor unable to tolerateUDCA,were
randomized to daily Placebo, OCA 5–10mg, or OCA 10mg.
Results: Thirty-two of 216 patients were treated at Italian
sites (Placebo, n=11; OCA 5–10mg, n=11; OCA 10mg, n=10).
In Italian patients, both OCA groups demonstrated significant
reductions in ALP (U/L) after 12 months of double-blind treat-
ment (Placebo: 43±108; OCA 5–10mg: −114±86, p<0.01; OCA
10mg: −132±104, p<0.01). This response was durable through
an additional 24 months of treatment during the OLE (Placebo:
−105±86, p<0.05; OCA 5–10mg: −140±78, p<0.01; OCA 10mg:
−122±110, p<0.05). After 12 months of double-blind treatment,
total bilirubin (mol/L) increased in the Placebo group (2.1±2.5),
but remained stable in OCA 5–10mg and OCA 10mg groups
(−0.6±3.5, p<0.05 and −1.1±1.9, p<0.05). The change fromBase-
line in total bilirubin at month 24 of the OLE remained relatively
stable (Placebo: 1.1±5.4; OCA 5-10mg: −0.3±4.5; OCA 10mg:
0.4±5.7). Five (45%) of the Placebo patients in the double-blind
phase and 8 (80%) of the Placebo patients initiating OCA in the OLE
experienced pruritus.
Conclusions: OCA given to Italian patients resulted in signifi-
cant improvements in markers of cholestasis and hepatic damage.
A durable responsewas evident throughout theOLE demonstrating
the safety and efficacy of long-term OCA treatment.
http://dx.doi.org/10.1016/j.dld.2017.01.044
